Inhibrx Stock News

Inhibrx (NASDAQ:INBX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Friday, Zacks.com reports. The firm presently has a $43.00 price objective on the stock. Zacks Investment Researchs price objective suggests a potential upside of 9.75% from the stocks current price. According to Zacks, [] The post Zacks Investment Research Upgrades Inhibrx (NASDAQ:INBX) to Buy appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Inhibrx (NASDAQ:INBX) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. They currently have $43.00 price objective on the stock. According to Zacks, Inhibrx Inc. is a clinical-stage biotechnology company. The companys pipeline is focused on oncology and []

Zacks Investment Research lowered shares of Inhibrx (NASDAQ:INBX) from a buy rating to a hold rating in a report released on Thursday morning, Zacks.com reports. According to Zacks, Inhibrx Inc. is a clinical-stage biotechnology company. The companys pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Several other []

Inhibrx (NASDAQ:INBX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, Inhibrx Inc. is a clinical-stage biotechnology company. The companys pipeline is focused on oncology and orphan diseases. Inhibrx Inc. is based in SAN []

The FDA has granted Orphan Drug designation to Inhibrx Inc''s (NASDAQ: INBX ) INBRX-109 for chondrosarcoma. Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the U.S. and the European Union. Currently, there are no therapeutics approved for the treatment of chondrosarcoma. INBRX-109 is a precision-engineered, tetravalent Full story available on Benzinga.com

Goldman Sachs Group Inc. lifted its holdings in shares of Inhibrx, Inc. (NASDAQ:INBX) by 21.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,582 shares of the companys stock after buying an additional 8,998 shares during the quarter. Goldman []

The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.

Inhibrx, Inc. (NASDAQ:INBX)s stock price was down 5.3% during mid-day trading on Wednesday . The stock traded as low as $37.78 and last traded at $37.78. Approximately 93 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 174,831 shares. The stock had previously closed at $39.90. Several research []

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA

The mean of analysts' price targets for Inhibrx, Inc. (INBX) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among anal

The mean of analysts' price targets for Inhibrx, Inc. (INBX) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among anal

Zacks Investment Research upgraded shares of Inhibrx (NASDAQ:INBX) from a hold rating to a buy rating in a research note released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $50.00 price objective on the stock. According to Zacks, Inhibrx Inc. is a clinical-stage biotechnology company. The companys pipeline is focused on oncology and []

Northern Trust Corp increased its holdings in Inhibrx, Inc. (NASDAQ:INBX) by 156.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 245,837 shares of the companys stock after purchasing an additional 149,977 shares during the quarter. Northern Trust Corp owned approximately 0.65% []

Related Stocks: INBX , BNTX , ADGI , VIR , FULC , AVTE , BEAM , EPIX , KROS , RLAY , GBIO ,

Related Stocks: INBX , IMTX , CMPS , GOSS , BCAB , CRVS , BCYC , APLS , ZNTL , AYLA , WVE , MCRB , ALEC , ANVS , CGEM , CCXI , CHAQ.U , IMAB ,